Healthcare Outlook
Palliative Care Market Observational Studies by Top Companies to 2026
Palliative care is specialized medical care for people suffering from serious illness. This type of care is focused on relief from the symptoms and stress of a serious illness. Palliative care is provided by a specially-trained team of doctors, nurses, and other specialists. Palliative care teams specialize in treating people suffering from serious illnesses such as cancer, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), kidney disease, Alzheimer’s, Parkinson’s, Amyotrophic Lateral Sclerosis (ALS) and others. Palliative care market size is increasing in higher income countries such as European countries and Japan due to rising geriatric population suffering from chronic illness. Palliative care also includes equipment such as wheelchairs, walkers, crutches, oxygen equipment, blood pressure monitors, etc.
Request Free Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2538
Global Palliative Care Market Drivers
The palliative care market revenue is expected to witness significant growth over the forecast period, owing to increasing demand for palliative care centers by patients suffering from chronic illness. For instance, according to Center to Advance Palliative Care (CAPC), in North America, the prevalence of hospitals with a palliative care team increased from 658 to 1,831, which is around 178% increase from 2000 to 2016.
Increasing geriatric population suffering from chronic illness is contributing to the palliative care market size. Palliative care centers are widely involved in taking care of elderly patients affected with chronic illness. According to National Council on Aging 2018 report, around 80% of older adults have at least one chronic disease and 77% have at least two chronic diseases such as heart disease, cancer, stroke, and diabetes.
Global Palliative Care Market: Regional Analysis
North America is expected to hold the dominant position in the palliative care market, owing to increased spending on healthcare facilities, infrastructure, and healthcare policies for treatment of chronic diseases. For instance, according to National Health Expenditure Accounts (NHEA), the U.S. health care spending increased 3.9% in 2017 reaching US$ 3.5 trillion or US$ 10,739 per person, compared to 2016 which was US$ 3.3 trillion
Asia Pacific palliative care market revenue is expected to witness significant growth owing to increasing patient base of chronic illness in older adults. For instance, China has the largest population in the world, according to the WHO 2013 report, out of the 202 million older people in China, more than 100 million had at least one chronic non-communicable disease such as ischemic heart disease, cancer, stroke, arthritis and dementia. Furthermore, many had multiple chronic diseases at the same time.
Global Palliative Care Market: Competitive Landscape
Key players operating in the global palliative care market include Vitas Healthcare Corporation, Skilled Healthcare Group Incorporated, Sunrise Senior Living LLC, Kindred Healthcare Incorporated, Gentiva Health Services Incorporated, Home Instead Senior Care Incorporated, Amedisys Incorporated, and Genesis HealthCare Corporation.
Global Palliative Care Market: Taxonomy
The global palliative care market is segmented on the basis of service type, application, and region.
By Service Type
Private Residence Care
Hospital Inpatient Care
Nursing Home Care
Residential Facility Care
By Application
Cancer
Cardiac Diseases
Chronic Obstructive Pulmonary Disease (COPD)
Kidney Diseases
Neurologic Diseases
Others
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/ongoing-insight/palliative-care-market-2538
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Nasal Polyps Treatment Market Study A Variety of Different Things
Nasal polyps are benign growths occurring inside the paranasal sinuses and in the lining of the nose. Generally, it is characterized as a teardrop shaped and yellowish brown or pink in color. The size of the polyps may vary and can be clustered or may grow alone. These can cause severe infections and breathing difficulties, causing sleep apnea in some cases. The cause of nasal polyps can be due to asthma, allergic infections, sinus infections, cystic fibrosis, etc. There are no particular symptoms that develop but an inflammation in the lining of the nose can occur.
To Access the Free Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/2775
Global Nasal Polyps Treatment Market Drivers
Key players are constantly focused on developing novel approaches for treatment of nasal polyps, which is expected to impel the global nasal polyps’s treatment market growth. For instance, in April 2018, Intersect ENT Inc. launched a product, SINUVA. It is a sinus implant and used for treating nasal polyps. It is a new way of treatment in patients with the past sinus surgeries. This implant contains 1.35 mg mometasone furoate which is delivered, directly to the polyps. It is implanted for a definite period of time (90 days).
Furthermore, in June 2019, Novartis AG revealed the phase III clinical trial study of Xolair, Omalizumab. It is a monoclonal antibody used for treating nasal polyps. It tends to target and block the immunoglobulin E. It was observed that the medication was generally well-tolerated in patients. Hence, such developments of treatment for nasal polyps are expected to fuel the global nasal polyps treatment market growth.
Increasing approvals from regulatory bodies related to nasal polyps treatment is expected to drive the global nasal polyps treatment market growth. For instance, in June 2019, Dupixent received an approval from the U.S. Food & Drug Administration (FDA) for treating with nasal polyps. It was manufactured by Sanofi in partnership with Regeneron Pharmaceuticals Inc. It is the first treatment that got approved for chronic rhinosinusitis with nasal polyps. It is used when the oral steroids are unable to control the inflammation and to avoid the surgical method. Hence, such approvals are expected to impact positively on the global nasal polyps treatment market growth.
Global Nasal Polyps Treatment Market Regional Analysis
North America is expected to hold a dominant position in the global nasal polyps treatment market. Factors such as higher prevalence of asthma is expected to be a major contributor in the North America’s nasal polyps treatment market growth. Nasal polyps are triggered due to asthma and also at the same time nasal polyps can cause asthma. For instance, according to American Academy of Allergy, Asthma & Immunology 2017, published data, around 28% to 40% patients with nasal polyps are diagnosed with asthma. According to the same source, around 19% to 39% patients get nasal polyps who are already suffering from asthma. Such increasing prevalence may increase the demand for treatment of nasal polyps thereby expected to propel the global nasal polyps treatment market growth.
Global Nasal Polyps Treatment Market Key Players
Some of the major players operating in the global nasal polyps treatment market include, Intersect ENT Inc., GlaxoSmithKline Plc, Merck Sharp and Dohme Corp, Teva Branded Pharmaceutical Products R and D Inc., Norton Waterford Ltd, Sanofi, Regeneron Pharmaceuticals Inc., Fougera Pharmaceuticals Inc., Glenmark, and Taro Pharmaceuticals Industries Ltd.
Global Nasal Polyps Treatment Market Taxonomy
By Drug
Fluticasone
Mometasone
Fluticasone
Beclomethasone
Prednisone
Others
By Route of Administration
Oral
Nasal
Injectable
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/ongoing-insight/nasal-polyps-treatment-market-2775
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Foley Catheters Market Present Scenario and Growth Prospects To 2026
Foley catheters are the most commonly used devices for managing urinary incontinence. The design of Foley catheters has not fundamentally changed over the time, although device manufacturers have introduced several modification to lessen the risk of trauma and infection associated with Foley catheters. Improvements in materials have been made from the original latex rubber to silicone and a variety of coatings such as Teflon and hydrogel have been used. The size and shape of the drainage eyes have been modified to enhance urine flow and reduce clogging. Antiseptic and antibiotic coatings on catheters have also been applied to combat the bacteria introduced into the bladder by the catheter. However, the results of these changes have been inconclusive and the Foley catheter design is believed to be a major cause for many of the complications, including urinary tract infections (UTIs), bladder spasms, cystitis, and possibly an increased risk of bladder cancer.
To Access the Free Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/2808
Foley Catheters Market- Drivers
Technological advancements in Foley catheters such as introduction of novel coatings and engineering strategies and advantages such as easy accessibility and affordability are major factors driving the Foley catheters market growth during the forecast period. The novel coating of foley catheters which may prevent catheter-associated urinary tract infections (CAUTI)
Besides, increasing prevalence of kidney and other renal disorders is expected to drive growth of the Foley catheters market during the forecast period. For instance, according to National Kidney Foundation of the US, 10% of the population worldwide was affected by chronic kidney disease in 2015.
Foley Catheters Market-Regional Analysis
On the basis of region, the Foley catheters market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the Foley catheters market over the forecast period, due to increasing prevalence of urological disorders in the US. For instance, according to Urology Care Foundation in 2015, a quarter to a third of men and women in the U.S. suffer from urinary incontinence. Around 33 million people in the US have overactive bladder representing symptoms of urgency, frequency and with or without urge incontinence.
Followed by North America, Europe is expected to dominate the market for Foley catheters, owing to increasing number of hospitalized patients due to various medical complications. For instance, according to European Commission 2016 data, the average duration of hospital stay in European countries was 5.3 days to 9.6 days in 2016.
Foley Catheters Market-Competitive Landscape
Key players operating in the Foley catheters market include, C.R. Bard, Inc., Teleflex Incorporated, Medtronic, Inc., ConvaTec, Inc., Medline Industries, Inc., B. Braun Melsungen AG, Create Medic Co. Ltd., Fuji Systems Corporation, and Cook Medical Group, Inc.
Foley Catheters Market-Taxonomy
The Foley catheters market is segmented on the basis of product type, material, end user, and region.
By Product Type:
Two-way Catheters
Three-way Catheters
Four-way Catheters
By Material Type:
Latex
Silicon
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/ongoing-insight/foley-catheters-market-2808
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Janus Kinase Inhibitor Market Demands and Growth Prediction till 2026
Janus kinase (Jak) is a family of non-tyrosine receptor kinases, which play a major role in cytokine signaling. Binding of cytokines (ligand) to receptor results in receptor dimerization and ultimately activates Jak-mediated phosphorylation of the receptor. Jak phosphorylates STAT (Signal Transducer and Activator of Transcription proteins) and STAT dimer carries out the transcription of genes which are critical for signal cascade involved in inflammatory and immune response. Therefore, Janus kinase is used as a target in treatment of autoimmune disorders such as rheumatoid arthritis.
To Have A Snippet Of The Report, Request Sample: https://www.coherentmarketinsights.com/insight/request-sample/2553
Janus Kinase Inhibitor Market Drivers
Jak inhibitors are increasingly preferred for industrial research due to their critical role in immune response signaling. For instance, in June 2018, Eli Lilly and Company announced approval from the U.S. Food and Drug Administration (FDA) for OLUMIANT (baricitinib) — an oral medication for rheumatoid arthritis in adults. Approval was granted for use of baricitinib in combination with methotrexate (MTX) or other disease-modifying antirheumatic drugs (DMARDs) or as monotherapy. The drug inhibits activation of Jak1/2 (Janus kinase 1 and 2) and decreases the production of inflammatory cytokines, thereby inhibiting inflammatory response. Therefore, increasing launch of new drugs is expected to fuel the global janus kinase inhibitor market growth over the forecast period.
Psoriatic arthritis is a form of arthritis, which is characterized by red patches of skin with silvery scales. Tofacitinib is a janus kinase inhibitor, which modulates cytokines that are required for signaling of inflammatory and immune response. Inclusion of new treatment options is expected to boost the global janus kinase inhibitor market growth over the forecast period. For instance, in December 2017, Pfizer Inc. received approval from the U.S. FDA for XELJANZ (TOFACITINIB) for treatment of adult patients suffering from psoriatic arthritis (PsA).
Janus Kinase Inhibitor Market Regional Analysis
The Janus kinase pathway mediates intracellular signaling of over sixty cytokines. Dysregulation of cytokines causes systemic lupus erythematosus (SLE) -- an autoimmune disorder and chronic disease, which is characterized by inflammation of connective tissues such as cartilage and blood vessel lining. According to National Center for Biotechnology Information (NCBI), the highest prevalence and incidence of SLE was in recorded in North America (23.2/100 000 person) during the period August 2013- September 2016. Therefore, high prevalence of SLE is expected to boost North America janus kinase inhibitor market growth over the forecast period.
Janus Kinase Inhibitor Market Key Players
Some of the key players operating in the global Janus kinase inhibitor market include, Eli Lilly and Company, Astellas Pharma Inc., Pfizer Inc., Baxter International Inc., Novartis International AG, Gilead Sciences Inc., Sierra Oncology, Inc., CTI BioPharma Corp., and Incyte Corporation.
Janus Kinase Inhibitor Market Taxonomy
The global janus kinase inhibitor market is segmented on the basis of drugs, indication, distribution channel and regions.
By Drugs
Baricitinib
Tofacitinib
Ruxolitinib
Pipeline drugs
- Peficitinib
By Indication
Rheumatoid arthritis
Psoriatic arthritis
Systemic lupus erythematosus
Others
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/ongoing-insight/janus-kinase-inhibitor-market-2553
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Androgen Deprivation Therapy (ADT) Market Research On Trends to 2026
Androgens are male sex hormones responsible for masculine characteristics such ad muscular build, deeper voice, and facial hair. Most of the androgens are produced in testes and their two most common types are dihydrotestosterone (DHT) and testosterone. Along with normal functions, androgens also contribute to prostate cancer cell growth, especially during early stages of the cancer. Androgen deprivation therapy, also called androgen suppression therapy, is used either to reduce the production of androgens in the patient’s body or to modulate the way androgens work, thus ultimately inhibiting growth of prostate cancer cells.
To Access the Free Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/2559
Androgen Deprivation Therapy (ADT) Market Drivers
Key players in the market are focusing on research to develop new drugs and broaden the indication label of current drugs for treatment of androgen deprivation therapy (ADT), which is expected to boost the global androgen deprivation therapy (ADT) market growth over the forecast period.
For instance, in February 2018, Janssen Pharmaceutica, a subsidiary of Johnson & Johnson received approval for its drug ERLEADA (apalutamide) in treatment of non-metastatic castration-resistant prostate cancer (CRPC). ERLEADA is a next-generation androgen receptor inhibitor, which belongs to the class of drugs anti-androgens and blocks the effect of testosterone to slow down the process of tumor growth and metastasis. It is the first U.S. Food and Drug Administration (FDA) approved drug for the treatment of patients with non-metastatic CRPC.
Similarly, in July 2018, Pfizer Inc. and Astellas Pharma Inc. received approval from the U.S. FDA for XTANDI (enzalutamide) that is indicated for the treatment of non-metastatic CRPC along with its existing indication for CRPC. XTANDI is an androgen receptor inhibitor and works by inhibiting the effects of testosterone, thereby slowing tumor growth and metastasis. These factors are expected to have a positive impact on the global androgen deprivation therapy (ADT) market growth over the forecast period.
Androgen Deprivation Therapy (ADT) Market Regional Analysis
Approval for new drugs is expected to boost the global androgen deprivation therapy (ADT) market growth over the forecast period. For instance, in November 2017, European Commission (EC) granted approval to Janssen-Cilag International NV (Janssen) for broadening the existing marketing authorization for its drug Zytiga (abiraterone acetate). The approval enables the company to include the drug in treatment of metastatic prostate cancer’s early stages along with ADT. Such new drug approvals are expected to propel Europe androgen deprivation therapy (ADT) market growth over the forecast period.
Androgen Deprivation Therapy (ADT) Market Key Players
Some of the major players operating in the androgen deprivation therapy (ADT) market include, Pfizer Inc., Astellas Pharma Inc., Johnson & Johnson, Novartis International AG, Veru Inc., Sanofi S.A., GlaxoSmithKline plc, Bayer AG, Orion Corporation, and AstraZeneca Plc.
Androgen Deprivation Therapy (ADT) Market Taxonomy
The global androgen deprivation therapy (ADT) market is segmented on the basis of drug class, route of administration, distribution channel, and regions.
By Drug Class
Antiandrogens
Flutamide
Bicalutamide
Nilutamide
Enzalutamide
Luteinizing hormone-releasing hormone (LHRH) agonists
Leuprolide
Goserelin
Triptorelin
Histrelin
LHRH antagonist
Degarelix
Abiraterone
Others
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/ongoing-insight/androgen-deprivation-therapy-adt-market-2559
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
 Market Research On Trends to 2026)
Cordyceps Sinensis and Militaris Extract Market Scrutinized In New Research By 2026
Cordyceps Sinensis and C. militaris is a combination of parasitic fungus species and dead caterpillars that offer several potential health applications. It has been used in Traditional Chinese medicine, and Tibetan medicine as a remedy for around 21 ailments such as low immunity, high blood pressure etc. Cordyceps spores grow inside the caterpillar’s body and infect it, thus slowly degrading the living larva and mummify it in the soil. A cordyceps stem eventually emerges from head part of the caterpillar.
Major active ingredients in cordyceps sinensis extract include cordycepin, adenosine, exopolysaccharide fraction (EPSF), cordyglucans, and monosaccharide saponin. Scientific studies and clinical trials have found that cordyceps sinensis extract can aid treatment of diabetes, high cholesterol, and hypertension. Furthermore, it boosts immunity and acts as a stress reliever in stress related disorders.
The global cordyceps sinensis and militaris extract market size was valued at US$ 473.4 million in 2018, and is expected to witness a CAGR of 10.4% during the forecast period (2018 – 2026).
Request Free Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/2578
Increasing emergence of traditional Chinese medicine in medicinal community is expected to drive growth of the cordyceps sinensis and militaris extract market
Traditional Chinese medicine (TCM) Cordyceps sinensis and C. Militaris are the potential bio-metabolites for herbal medicines. This cordyceps category has shown considerable significance in several clinical and biotechnological applications such as genetic and nutritional requirements.
TCM comprises traditional Chinese medicinal materials, decoction pieces, Chinese patented medicines, herbal extracts, and healthcare products. Internationalization of TCM products is expected to help other countries and regions to develop and produce traditional Chinese medicines in order to serve the healthcare industry. Among all the TCM products, Cordyceps sinensis is the most explored species, followed by C. millitaris.
For instance, as per the National Center for Biotechnology Information report, in 2016, the total import and export value of TCM was accounted for US$ 4.6 Bn, which represented 4.45% of the total value of import and export of Chinese pharmaceutical products. However, the value of export declined by 9.13%, from US$ 3.77 Bn in 2015 to US$ 3.426 Bn in 2016, while the import value increased by 14.50%, from US$ 1.025 Bn in 2015 to US$ 1.174 Bn in 2016.
Cordyceps Sinensis and Militaris Extract Market- Regional Analysis
Regional segmentation of the global Cordyceps Sinensis and Militaris Extract Market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Manufacturers in North America region are importing cordyceps sinensis extract to produce different types of medical formulations such as tablets and capsules. For instance, in August 2018, HANAH Life, the developer of Ayurvedic super food HANAH ONE, launched its Cordyceps+ in the North America market. Cordyceps+ is a combination of wild Bhutanese Cordyceps sinensis, with eight other herbs and minerals. The price of HANAH Cordyceps+ is US$168 for 30 capsules in the U.S. Furthermore, increasing number of patients with mental disorders is expected to significantly expand adoption of cordyceps sinensis extracts as it has immense benefits in lowering symptoms related to mental disorders such as depression, anxeity.
Cordyceps Sinensis and Militaris Extract Market - Competitive Landscape
Key players operating in the cordyceps sinensis and militaris extract market include Naturalin bio-resources co., Ltd, The Lubrizol Corporation, Quyuan sunnycare Inc., Shanghai Kangzhou Fungi Extract Co., Ltd., Xi'an Saina Biological Technology Co., Ltd. (Herbsino), Dalong Biotechnology Co., Ltd, Health Choice Limited, Nutrastar International Inc., Nutra Green Biotechnology Co., Ltd.
Detailed Segmentation:
Global Cordyceps Sinensis and Militaris Extract Market, By Formulation:
Tablet/ Capsules
Liquid
Powder
Global Cordyceps Sinensis and Militaris Extract Market, By Application:
Medicine
Dietary Supplements
Food Additives
Global Cordyceps Sinensis and Militaris Extract Market, By Strain Type:
Cordyceps Sinensis
Cordyceps Militaris
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/cordyceps-sinensis-and-militaris-extract-market-2578
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Hepatic Encephalopathy Market to Incur Meteoric Growth By 2027
Hepatic encephalopathy (HE) is a neuropsychiatric complication commonly associated with the liver disease: cirrhosis. The inability of the liver to metabolize ammonia results in a buildup of ammonia, which can cross the blood–brain barrier and cause significant neurocognitive impairment. A significant number of patients with cirrhosis may experience HE and may be at high risk of recurrent HE.
The severity of hepatic encephalopathy can be broadly categorized into two classes: Covert Hepatic Encephalopathy (CHE) and Overt Hepatic Encephalopathy (OHE). OHE is associated with high rates of mortality and hospitalizations and poor quality of life. Factors such as infections, gastrointestinal bleeding, metabolic disturbance, and dietary protein overload may cause OHE. According to a study conducted by the U.S. National Library of Medicine in 2016, 30 to 50% of patients who have cirrhosis during their clinical care are likely to develop OHE.
Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2596
The global hepatic encephalopathy market was valued at US$ 2,408.3 Mn in 2017, and is expected to witness a CAGR of 6.3% during the forecast period (2018 – 2026).
Increasing number of drugs in pipeline for the treatment of HE is expected to drive the market growth during the forecast period
There are different types of therapeutic drugs in pipeline for the treatment of HE. Increasing number of products in pipeline for the treatment of HE is expected to drive growth of the market over the forecast period.
Umecrine Cognition, a Sweden-based pharmaceutical company, is developing a therapy that represents a new target class for several major central nervous system (CNS)-related disorders. The lead compound GR3027 is presently in clinical development for HE. The company plans to demonstrate Phase II data of GR3027 for the treatment of HE in 2020.
Increasing prevalence of various types of liver diseases is expected to aid in the market growth
HE is a sign of poor prognosis and correlates with mortality in both patients with acute liver failure and those with cirrhosis associated with end stage liver disease. Liver cirrhosis is a gastroenterological condition that is characterized by a slow, progressive, and irreversible replacement of liver cells by fibrous tissue (scar) that prevents normal liver functioning.
According to the National Center for Biotechnology Information (NCBI): 2014, generally liver cirrhosis affects up to 1% of the U.S. and EU population. Between 180,000 and 290,000 patients with cirrhosis in the U.S. are hospitalized due to complications of HE. Once HE develops, mortality reaches 22-35% after five years. HE is also associated with increased hospitalization and treatment costs. Moreover, subtle signs of HE are observed in around 70% of patients with cirrhosis.
Key Players
Key players operating in the global hepatic encephalopathy market include, ASKA Pharmaceutical Co., Ltd., Cosmo Pharmaceuticals N.V., Lupin Limited, Kaleido Biosciences, Kannalife Sciences, Inc., Bausch Health Companies Inc., Ferring Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, and Norgine B.V.
Detailed Segmentation:
Global Hepatic Encephalopathy Market, By Drug Class:
Antibiotic
Laxatives
Others
Global Hepatic Encephalopathy Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/hepatic-encephalopathy-market-2596
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Heparin Market to Record an Impressive Growth Rate by 2026
Heparin is used to prevent or treat certain blood vessel, heart, and lung conditions. It is also used in blood transfusion, blood samplings during prophylaxis treatment, and for treatment of blood clotting disorders Heparin may be used to diagnose and treat a serious blood condition called disseminated intravascular coagulation. Heparin is sometimes used alone or in combination with aspirin to prevent pregnancy loss and other problems.
The global heparin market size was valued at US$ 9.4 billion in 2017 and is expected to witness a CAGR of 5.1% over the forecast period (2018 – 2026).
Request a Sample of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/2602
Increasing incidences of coronary heart disease, pulmonary embolism, and deep vein thrombosis is expected to drive growth of the heparin market
Heparin is widely used clinically for dialysis, deep vein thrombosis (DVT) treatment, and most cardiac surgeries. It is also used to prevent blood clotting during open-heart surgery, kidney dialysis, bypass surgery, and blood transfusions. Kidney dialysis procedure is increasing with rising chronic kidney disease, worldwide. For instance, according to Kidney Care UK 2016 report, about 3 million people in the U.K. are suffering from chronic kidney disease (CKD).
Furthermore, increasing number of surgeries and rising prevalence of diseases such as deep vein thrombosis and coronary heart disease, are fueling demand for heparin, eventually driving growth of the heparin market, during the forecast period. According to the American Heart Association 2018 report, coronary heart disease accounts for 1 in 7 deaths in the U.S., killing over 366,800 people every year. As per the same source, the overall prevalence for myocardial infarction (MI) in the U.S. is about 7.9 million, or 3 percent in U.S. adults.
Heparin Market - Regional Insights
On the basis of region, the global heparin market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Europe heparin market is expected to generate significant revenue share during the forecast period, owing to growing geriatric population and rising prevalence of long-term survivors of acute myocardial infarction (AMI). Survivors of AMI are at high risk of a recurrent myocardial infarction, as well as other manifestations of cardiovascular disease such as stroke. According to Lancet journal, 2017 report, acute myocardial infarction is the leading cause of hospital admissions and mortality in the UK and across the world.
Heparin Market - Competitive Landscape
Key players operating in the global heparin market include Anselm Pharmaceuticals, Baxter International Inc., B. Braun Melsungen AG, Bristol-Myers Squibb Co., Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., LEO Pharma A/S, Pfizer, Inc., Sanofi S.A., Syntex S.A., Teva Pharmaceutical Industries Ltd., and United Biotech (P) Ltd.
Detailed Segmentation:
Global Heparin Market, By Product Type:
Unfractionated Heparin (UH)
Low Molecular Weight Heparin (LMWH)
Ultra-low Molecular Weight Heparin (ULMW)
Global Heparin Market, By Dosage Form:
Injection
Solutions
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/heparin-market-2602
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Growth Analysis to 2026
Chronic Inflammatory Demyelinating polyneuropathy (CIDP) is a rare neurological disorder which causes paralysis (impairment of sensory function in limbs). It occurs due to the inflammation of nerve roots, peripheral nerves, and destruction of the fatty protective covering (myelin sheath) over the nerves. It slows down the transmission of nerve signals, thus leading to destruction of nerve fibers. It can be treated with corticosteroids or in combination with an immunosuppressant, plasma exchange, and intravenous immunoglobulin therapy.
Request a Sample of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/2609
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Drivers
Increasing drug approvals by regulatory authorities is expected to boost the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth. For instance, in March 2017, CSL Behring received U.S. Food and Drug Administration (FDA) approval for Privigen, an immunoglobulin therapy for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) disorder. 207 patients were treated with Privigen for 13 weeks and 73% out of these 207 patients responded to it in clinical trials. Furthermore, in March 2018, CSL Behring received U.S. FDA approval for Hizentra, which is a type of subcutaneous immunoglobulin therapy that prevents relapsing neuromuscular disability. It offers a convenient treatment type, in which patients can infuse themselves. The approval was based on the phase III results of the clinical trial. These factors are expected to propel the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth.
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Regional Analysis
North America is expected to hold a dominant position in the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market. Factors such as initiatives from governments and other organizations are expected to have an influence on the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth. For instance, in April 2019, Guillain-Barre syndrome & Chronic Inflammatory Demyelinating Polyneuropathy (GBS | CIDP) international foundation announced that it is going to celebrate May as GBS | CIDP awareness month. They plan to create awareness about the foundation’s legislative initiatives for CIDP patients through social media and campaigns. The initiative is for creating a bill which includes the establishment of the Medicare Part B Home Infusion Demonstration Project, and increase in funds for treatment of CIDP patients. These factors are expected to have a positive impact on the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Key Players
Some of the major players operating in the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market include CSL Behring, Kedrion S.p.A., Takeda Pharmaceutical Co. Ltd., Shire Plc., GeNeuro SA ,Baxter International Inc., Octapharma AG and Grifols S.A., Teijin Pharma Ltd. and Nihon Pharmaceutical Co. Ltd.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment Market Taxonomy
The global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market is segmented by treatment type, distribution channel and regions.
By Treatment Type
- Intravenous immunoglobulin therapy
Privigen
Hizentra
Gamunex-C
Tegeline
Others
- Corticosteroids
- Others
By Distribution Channel
Hospital pharmacies
Retail pharmacies
Online pharmacies
Browse In-Depth Analysis Research Report @ https://www.coherentmarketinsights.com/ongoing-insight/chronic-inflammatory-demyelinating-polyneuropathy-cidp-treatment-market-2609
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Suprapubic Catheter Market Future Challenges and Analysis 2026
Suprapubic catheter is a hollow flexible tube intended to create a passage between the urinary bladder and skin to drain urine from the bladder of the individual suffering from obstruction of normal urinary flow. Swelling of the prostate, traumatic disruption of urethra, congenital defects of the urinary tract, or by obstructions of kidney stones passed into the urethra can block the normal urinary flow. Suprapubic catheter has fewer chances of causing infection to individuals.
Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/2616
Market Dynamics
Increasing prevalence of kidney disorders such as kidney stone (Urolithiasis) is expected to drive the suprapubic catheter market growth. When the ureter gets blocked due to the presence of kidney stone, suprapubic catheters are used to create passage for urine flow. For instance, in November 2018, National Health and Nutrition Examination Survey (NHANES) published the study data for the prevalence of kidney stone in the U.S. According to NHANES, for 2013–2014 NHANES cycle, the prevalence of kidney stone in the U.S. was 10.1%. Moreover, NHANES also stated that the prevalence of kidney stones (KSs) was the highest in males older than 60 years (17.8%), followed by males 40–59 years old (12.6%). The study also showed that the prevalence of kidney stone in males was stable while it was increasing in females.
Increasing product launches is expected to drive growth of the suprapubic catheter market
New product launches to normalize the urine flow in medical conditions and surgeries such as kidney stones and gynecologic procedures are expected to drive the suprapubic catheter market growth. For instance, in September 2016, CompactCath launched its intermittent urinary catheter to address the issues that patients have while self-catheterizing on daily routines. Furthermore, in 2014, CompactCath received the U.S. Food and Drug Administration clearance for the intermittent urinary catheter.
Suprapubic Catheter Market- Regional Analysis
Regional segmentation of the global suprapubic catheter market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America suprapubic catheter market is expected to account for the largest market share over the forecast period, owing to presence of key players such as Becton, Dickinson and Company, Bard Medical, Cook Medical, and Teleflex Incorporated. For instance, in February 2017, Cook Medical introduced Universa Malecot Drainage Catheter Suprapubic Set, a new set for percutaneous urinary drainage including introductory sets for initial catheter placement and suprapubic sets for suprapubic drainage.
Suprapubic Catheter Market - Competitive Landscape
Key players operating in the suprapubic catheter market include Amecath, Becton, Dickinson and Company, B. Braun Melsungen AG, Cook Medical, Teleflex Incorporated, Fortune Medical Instrument Corp, Degania Silicone Ltd., Bard Medical, Urovision GmbH, UroTech Inc., and UroMed.
Detailed Segmentation:
Global Suprapubic Catheter Market, By Indication:
Benign Prostate Hyperplasia
Urinary Incontinence
Others
Global Suprapubic Catheter Market, By Material:
Rubber
Plastic
Polyvinyl Chloride
Browse In-Depth Analysis Research Report @ https://www.coherentmarketinsights.com/market-insight/suprapubic-catheter-market-2616
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Fc Protein and Glycoengineered Antibodies Market to Reflect Steady Growth 2027
Monoclonal antibodies are developed by identical immune cells, which have a therapeutic use. The crystallized fragments (Fc) protein and glycoengineered antibodies are known as the next generation antibodies. These monoclonal antibodies are immunoglobulin G (IgG) type of molecules, which are attached to a glycan residue on crystallisable fragment. Glycoengineering is the method by which these antibodies are created. They have varied applications for the treatment of diseases such as multiple sclerosis and cancers.
Ask Sample Copy of Research: https://www.coherentmarketinsights.com/insight/request-sample/2626
Global Fc Protein and Glycoengineered Antibodies Market Drivers
Key players in the market are focusing on research and development activities and receiving approvals from regulatory bodies, which are expected to boost the global Fc protein and glycoengineered antibodies market growth over the forecast period.
For instance, in 2016, Genentech Inc. received approval from the U.S. Food and drug Administration (U.S. FDA) for Tecentriq (Atezolizumab). It is being used for the treatment of urothelial carcinoma. In March 2019, Tecentriq received its second approval from the U.S. FDA for the treatment of small lung cancer. Furthermore, in November 2017, TG Therapeutics, Inc. began its clinical trial of Ublituximab for the treatment of multiple sclerosis. It is currently in third phase of its clinical trial. Factors such as increasing product approvals and robust pipeline are expected to drive the global fc protein and glycoengineered antibodies market growth.
Global Fc Protein and Glycoengineered Antibodies Market Regional Analysis
North America region is expected to dominate in the global fc protein and glycoengineered antibodies market due to factors such as product launches, presence of leading manufacturers (such as F. Hoffmann La-Roche Ltd.), and active research and development in the field. Drugs such as Obinutuzumab (Gazyva), Mogamulizumab (Poteligeo), Atezolizumab (Tecentriq), and Durvalumab (Imfinzi) have been approved in the U.S. in 2013, 2018, 2016, and 2017 respectively.
Europe is expected to witness significant growth in the global Fc protein and glycoengineered antibodies market. Factors such as approval for new drugs is expected to drive the Europe’s Fc protein and glycoengineered antibodies market growth over the forecast period. For instance, in 2018, Kyowa Hakko Kirin Co. Ltd. received an approval from the European Commission to market the Poteligeo antibody in the European market. It is the first biological product that is being directed against chemokine receptor 4 (CCR4), which will be used for the treatment of Sezary syndrome that has been previously treated by systemic therapy. Such new drug approvals are expected to propel Europe Fc protein and glycoengineered antibodies market growth over the forecast period.
Global Fc Protein and Glycoengineered Antibodies Market Key Players
Some of the major players operating in the global Fc protein and glycoengineered antibodies market include Kyowa Hakko Kirin Co. Ltd., Merck KGaA, Boehringer Ingelheim International GmbH, AstraZeneca Plc, Amgen Inc., Genentech Inc., Five Prime Therapeutics Inc., Celldex Therapeutics, Clovis Oncology, and TG Therapeutics, Inc.
Global Fc Protein and Glycoengineered Antibodies Market Taxonomy
The global Fc protein and glycoengineered antibodies market is segmented on the basis of drug, application, and region.
By Drug
Approved Drugs
- Obinutuzumab (Gazyva)
- Mogamulizumab (Poteligeo)
- Atezolizumab (Tecentriq)
- Durvalumab (Imfinzi)
Pipeline Drugs
Ublituximab
Others
By Application
Oncology
Autoimmune Disease
Others
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/ongoing-insight/fc-protein-and-glycoengineered-antibodies-market-2626
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Androstenedione Market to Witness Moderate Growth Rate to 2026
Androstenedione is a steroid hormone, described as a ‘pro-hormone’, produced mainly in the testes in men and in the ovaries in women, which is used to increase the production of hormones testosterone and estrogen. Androstenedione is taken orally specifically to increase the testosterone level. By boosting testosterone levels, androstenedione is believed to improve the athletic performance, enhance recovery and growth from exercise, increase energy, keep red blood cells healthy, and increase the sexual desire and performance.
Androstenedione is taken orally in a contraceptive pills or capsules and is available in a spray form that is administered under the tongue for instant results. Common side effects of androstenedione in men include low sperm production, painful and prolonged erections, breast development, heart diseases, behavioral changes, and others. In women, side effects such as abnormal menstrual periods and depression are observed. Androstenedione can increase chances of breast, prostate, or pancreas cancer and it is poisonous to liver. The control of androstenedione is very complex due to its secretion from number of other glands and its rapid conversion to other hormones. The usual dosage of androstenedione is 50-100 milligrams in pill form twice daily.
Get The Inside Scoop Of The Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/2634
Global Androstenedione Market- Dynamics
Increase in adoption of androstenedione as a dietary supplement is major factor driving growth of the global androstenedione market. Young people and athletes frequently consume androstenedione to strengthen the body. Moreover, rising prevalence of various infectious inflammation diseases and arthritis are major factors expected to augment growth of the global androstenedione market in the near future. According to Arthritis Foundation, in 2015, prevalence of osteoarthritis in the U.S. was estimated at 30.8 million in adults and 14 million individuals in the U.S. have symptomatic knee arthritis. This is expected to increase adoption of androstenedione.
However, stringent government regulations is major factor restraining growth of the global androstenedione market. For instance, androstenedione is banned by the World Anti-Doping Agency (WADA) and International Olympic Committee (IOC), under the category of androgenic anabolic steroids. However, adverse effects of androstenedione include sustained increase in serum estrogen and increase in serum luteinizing hormone, lean muscle mass, and bone growth problem in children, thus restraining growth of the global androstenedine market. Furthermore, pregnant women are warned from using these pills as they are linked with higher risks of labor and cause of miscarriage.
Global Androstenedione Market- Regional Dynamics
Regional segmentation of the global androstenedione market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America, especially the U.S., is expected to hold dominant position in the global androstenedione market over the forecast period. For instance, according to international perspectives on sexual and reproductive health research, in 2015, North America, fertility control rate is decreased by 0.3%, thereby augmenting the global androstenedione market growth. In 2015, an estimated 1.3% adults (3 million) are reported being diagnosed by inflammatory bowel disease.
Global Androstenedione Market- Competitive Analysis
Market players are engaged in developing new products to maintain leading position in global androstenedione market. Androstenedione is marketed primarily to athletes as a potential anabolic agent and is also claimed to have beneficial effects on general well-being, libido, and quality of life.
Some of the key players operating in the global androstenedione market include BIOVET, Indo Phyto Chemicals, Goto Pharmaceutical, Kaizon, Jiufu, Darui, Yongning Pharma, Dahua Pharmaceutical, Sito Bio, Dongyao Pharmaceutical, and Huazong Pharmaceuticals.
Global Androstenedione Market- Market Taxonomy
On the basis product type, global androstenedione market is segmented into:
Androstenedione (4-AD)
Androstadienedione ( ADD)
On the basis of application, global androstenedione market is segmented into:
Infectious Inflammation
Arthritis
Fertility Control
Others
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/ongoing-insight/androstenedione-market-2634
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Hemodialysis Market To Witness Substantial Gains Over 2019-2027
Hemodialysis also termed as dialysis is a process of blood purification, when human kidney fails to do so (due to kidney failure or end-stage renal diseases). In end–stage renal diseases, toxic waste products, and extra fluids are built-up in the body. There is also imbalance of salts and minerals in the blood. A hemodialysis or kidney transplant is opted in such cases. A hemodialysis machine is used to perform hemodialysis. The Component present in a hemodialysis machine are – dialyzer, a dialysis solution (sterilized mineral ions), and tubes for passing of blood and dialysis solution. The blood flows through the tubes and enters into the machine, where the waste products are removed through the filter and the blood again is passed back to the body through the tubes.
Request a Sample Copy of Research: https://www.coherentmarketinsights.com/insight/request-sample/2651
Global Hemodialysis Market Drivers
Strategies such as partnerships, collaborations, mergers, and acquisitions, adopted by the key players are expected to drive the global hemodialysis market growth. For instance, in July 2018, B. Braun Medical Inc., a medical device company acquired bloodline portfolio business of NxStage Medical Inc., a medical technology company for expansion of their dialysis product portfolio. B. Braun Medical Inc. is going to add “Streamline Express” (bloodline manufactured by NxStage Medical Corporation), a tubing set used in hemodialysis machine into their product portfolio.
Furthermore, in October 2018, Baxter Healthcare Corporation, a medical device company collaborated with Mayo Clinic, a non–profit medical center, for establishment of renal care center in Florida, U.S. The purpose of setting up the center is to serve patients with kidney failure and trial of new products, including hemodialysis machines. This may allow higher adoption of hemodialysis machines by the healthcare institutions, thereby expected to drive the global hemodialysis market growth.
Furthermore, key players are constantly focused on developing new technology in hemodialysis, which is expected to propel the global hemodialysis market growth. For instance, in January 2019, Fresenius Medical Care AG & Co. KGaA, launched a 4008A dialysis machine. The 4008A dialysis machine incorporates high therapy standards and is cost–effective.
Global Hemodialysis Market Regional Analysis
North America is expected to dominate the global hemodialysis market over the forecast period. Initiatives taken by the government and other organizations may have a positive impact on the North America hemodialysis market growth. For instance, in April 2019, Baxter International Inc., a medical device company, the National Association for the Advancement of Colored People (NAACP, civil right organization), and the Alliance for Home Dialysis announced to conduct a Dialysis Health Imperative for Access, Choice, and Equity program (ACEP) for the third year. The purpose of this program is to raise awareness about the kidney failure diseases, risk associated with it, treatment options available, etc. Such initiatives may lead to higher adoption of hemodialysis treatment and thereby, is expected to support the global hemodialysis market growth.
Global Hemodialysis Market Key Players
Some of the major players operating in the global hemodialysis market include, Baxter Healthcare Corporation, B. Braun Medical Inc., Fresenius Medical Care AG & Co. KGaA, Toray Industries, Inc., Nikkiso Co. Ltd., JMS Co. Ltd., Diaverum Deutschland GmbH, Nipro Corporation, and Gambro.
Global Hemodialysis Market Taxonomy
The global hemodialysis market is segmented on the basis of component, hemodialysis type, end user, and region.
By Component
Dialyzer
Dialysis Solution
Tubes
Catheter
Others
By Hemodialysis Type
Conventional
Daily
Nocturnal
Browse Complete Research Report: https://www.coherentmarketinsights.com/ongoing-insight/hemodialysis-market-2651
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Physiotherapy Equipment Market Trends and Opportunities Forecast till 2027
Physiotherapy is used to treat conditions like injuries, fractures, joint disorders, and arthritis. Recently, with the development of technology, many types of physiotherapy equipment have been introduced in the market. Physiotherapy equipment has application in cardiovascular, neurological, and musculoskeletal disease. Growing incidence of cardiovascular and neurological disorders is expected to drive growth of the physiotherapy equipment market. Physiotherapy includes electrotherapy, hydrotherapy, exercise therapy, and cryotherapy.
Ask for Sample Copy of Research: https://www.coherentmarketinsights.com/insight/request-sample/2688
Physiotherapy Equipment market- Drivers
The physiotherapy equipment market size is expected to increase over the forecast period, owing to rising prevalence of neurological and cardiovascular disorders such as Parkinson’s disease, spinal cord and traumatic brain injuries. For instance, according to Parkinson’s foundation 2018, in U.S., around 60,000 patients are diagnosed with Parkinson’s disease each year.
Furthermore, with the increasing incidence of sports related accidents and injuries, demand of physiotherapy equipment for developing and restoring bodily functions and movement is expected to be the major factor driving the physiotherapy equipment market during the forecast period. For instance, according to Stanford Children Health report 2019, in the U.S., more than 775,000 children, aged 14 and younger, are treated in hospital emergency rooms for sports-related injuries each year.
Physiotherapy Equipment Market- Regional Analysis
On the basis of region, the physiotherapy equipment market is segmented into North America, Latin America, Europe, Asia pacific, Middle East, and Africa. North America is expected to hold dominant position in the physiotherapy equipment market during the forecast period, owing to increase in the incidence of cardiovascular and neurological disorder. For instance, according to American College of Cardiology report 2019, cardiovascular disease (CVD) remains the leading cause of death in the U.S.
Asia Pacific is expected to witness significant growth over the forecast period, owing to geriatric population. For instance, according to Population Census report in 2011, the geriatric population was nearly 104 million in India, which is expected to grow to 173 million by 2026.
Physiotherapy Equipment Market- Competitive landscape
Key players operating in the physiotherapy equipment market include DJO Global, Patterson Companies, Inc., HMS Medical System, BLT industries, Inc., A. Algeo limited, Enraf-Nonius B.V., EMS Physio Ltd., and Isokinetic.
Physiotherapy Equipment Market- Taxonomy
The physiotherapy equipment market is segmented on the basis of product type, application, end user, and region.
By product type
Ultrasound
Electric Muscle Stimulation
Exercise Bike
Isokinetic
Nordic Track
Others
By Application
Cardiovascular
Pediatric
Orthopedic and Musculoskeletal
Gynecology
Browse In-Depth Analysis Research Report: https://www.coherentmarketinsights.com/ongoing-insight/physiotherapy-equipment-market-2688
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Foot and Ankle Devices Market Growth Potential and Opportunity Outlook 2027
Foot and ankle devices are used for the treatment of injuries including diabetic foot, arthritis with the help of surgical procedures, etc. Ankle disorders can cause damage to bone, muscle, and soft tissues. Common disorders associated with the ankle disorder are sprain, tendonitis, and fractures. The people with diabetes are prone to have foot problems which develop due to prolonged periods of high blood sugar levels. Along with foot and ankle, these devices are used in ligament repair and reconstruction procedures including arthrodesis, internal fixation, and joint replacement.
Click the link to Get a Sample Copy of the Report: https://www.coherentmarketinsights.com/insight/request-sample/2702
Global Foot and Ankle Devices Market - Drivers
Increasing prevalence of road side accidents and sport injuries is expected to drive the global foot and ankle devices market over the forecast period. For instance, according to National Safety Council Analysis of U.S. (NSC), in 2017, in U.S. due to exercise and exercise equipment 526,000 injuries were reported while basketball, with 500,000 injuries. Furthermore, subsequent product launches, continuous innovation of devices by manufacturers drive the global foot and ankle devices market growth over the forecast period. For instance, in March 2017, Integra LifeSciences Holdings Corporation launched the Cadence Total Ankle System in the U.S., which is used to treat ankle arthritis by replacing the ankle joint with a prosthesis, which reduces the pain and allows the movement at the replaced joint.
Approvals received by products from regulatory bodies associated with the treatment of forefoot conditions expected to fuel growth of the market. For instance, in January 2019, OSSIO, an orthopedic fixation company, announced that its OSSIOfiber Bone Pin Family received 510(k) market clearance from the U.S. Food and Drug Administration (FDA). OSSIOfiber platform will have the broad application in spectrum of orthopedics as it is used commercially in foot and ankle segment for the treatment of forefoot conditions. Furthermore, increase in number of diabetic foot reconstruction, increase in number of osteoporosis, rise in elderly population, and rise in number of outpatient procedures have fueled growth of global foot and ankle devices market. According to NCBI, in 2018 approximately 200 million people suffer from osteoporosis and approximately 8.9 million fractures are caused by osteoporotic fractures.
Global Foot and Ankle Devices Market - Regional Insights
North America holds dominant position in the global foot and ankle device market. The primary reason behind the market’s growth in North America is increase in incidence of osteoporosis, rising demand for minimally invasive surgeries, and well established healthcare infrastructure.
Asia Pacific is expected to witness the fastest growth rate due to the presence of large patient pool, increasing awareness, and rising healthcare expenditure in the Asian countries.
Global Foot and Ankle Devices Market - Competitive Landscape
Some of the key players operating in the global foot and ankle devices market include DePuy Synthes, Wright Medical Technology, Inc., Advanced Orthopedic Solutions, Acumed, Bioretec, Stryker, Integra LifeScience Corporation, Zimmer Biomet, Ossio, Smith & Nephew plc., and Ossur.
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/ongoing-insight/foot-and-ankle-devices-market-2702
Global Foot and Ankle Devices Market - Market Taxonomy
On the basis of product type, the global foot and ankle devices market is segmented into:
Bracing and support devices
Joint implants
Soft tissue orthopedic devices
Orthopedic fixation devices
Prosthetics
On the basis of cause of injury, the global foot and ankle devices market is segmented into:
Trauma
Diabetes
Neurological Disorders
Osteoporosis
Others
To Get Instant Access, Purchase Report Here: https://www.coherentmarketinsights.com/insight/buy-now/2702
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Custom Recombinant Protein Production Services Market Trends and Opportunities to 2026
Recombinant proteins are used in development of novel therapies for severe chronic diseases such as cancer and other rare diseases. Recombinant protein production requires a special technique known as recombinant DNA (rDNA) technology. Recombinant proteins have immense potential in cancer therapy research and development. For instance, growth factors, immune checkpoint, and cell damage & oxidative stress proteins (preclinical stage) are utilized from recombinant proteins category for cancer therapy research.
Market Dynamics
Increasing demand for recombinant proteins for basic research has supported growth of the custom recombinant protein production services market. Recombinant therapeutic proteins are one of the fast-growing areas in molecular medicine. Various biopharmaceutical companies are focusing on development of biologics and subsequently biosimilars. Moreover, increasing expenditure in research has supported the market growth. The R&D spending of the U.S. is around 2.7% of its Gross Domestic Products (GDP) with highest R&D investments observed in the biotechnology segment in 2014, according to American Pharmaceutical Review.
Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/2737
Increasing funding in the field of life sciences is expected to propel growth of the custom recombinant protein production services market
Recombinant protein is a manipulated form of protein, which is encoded by genes. It is used in production of large quantities of protein, which is further used for manufacturing of therapeutic commercial products. Increasing government initiatives and funding in the field of life sciences is expected to boost growth of the market. For instance, Life Sciences Greenhouse of Central Pennsylvania offers early stage funding of up to US$ 1-2 million in the form of convertible debt or equity financing to viable life sciences companies, which have significant potential for commercial growth.
Moreover, advancements in bioreactor systems have facilitated production of recombinant protein within shorter time span, which in turn is expected to propel growth of the custom recombinant protein production services market over the forecast period. For instance, according to National Centre for Biotechnology Information (NCBI), in 2014, around 65.6% of clinical scale manufacturers and 42% of commercial manufacturers adopted single-use bioreactors for improvement in their bioprocessing.
Increasing research and development and product launches in North America is expected to bolster the market growth
North America is expected to hold dominant position in the global custom recombinant protein production services market, owing to increasing focus of regional players in research and development and product launches. For instance, in 2014, Western Blot Service CRO, a division of Altogen Lab, launched automated WES protein analysis and protein expression services, providing a complete platform to conduct protein expression studies.
Key Players
Major players operating in the custom recombinant protein production services market include, GenScript Biotech Corporation, Applied Biological Materials Inc., Eurofins Pharma Discovery Services, Abgent, OriGene Technologies, Inc., Crown Bioscience, Inc., BPS Bioscience, Inc., ProteoGenix, Kempbio, Inc., Novoprotein, Premas Biotech, Trenzyme GmbH, Atum, Novus Biologicals, LLC, Icosagen AS, LakePharma, Inc., Proteos, Inc., Aldevron, and Sino Biological Inc.
Detailed Segmentation:
Global Custom Recombinant Protein Production Services Market, By Expression System:
Mammalian
Bacteria
Insect
Yeast
Others
Global Custom Recombinant Protein Production Services, By End User:
Research Institutes
Biotechnology and Pharmaceutical Companies
Contract Research Organizations
Others
Browse In-Depth Analysis Research Report: https://www.coherentmarketinsights.com/market-insight/custom-recombinant-protein-production-services-market-2737
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
